Severe Raynaud's phenomenon with chronic hepatis C disease treated with interferon.
Severe Raynaud's phenomenon developed in a 5-year-old girl with chronic hepatitis C infection at the fifth month of interferon therapy in the absence of cryoglobulinemia and other conditions commonly associated with secondary Raynaud's phenomenon. Although interferon therapy was promptly discontinued, Raynaud's phenomenon persisted for 4 months with appearance of necrotic-ulcerous lesions at the tips of fingers.
Iorio
Raffaele
R
Department of Pediatrics, University of Naples Federico II, Italy. riorio@unina.it
Spagnuolo
Maria Immacolata
MI
Sepe
Angela
A
Zoccali
Stefania
S
Alessio
Maria
M
Vegnente
Angela
A
D001774:Blood Chemical Analysis; D002675:Child, Preschool; D003449:Cryoglobulinemia; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D011928:Raynaud Disease / Q000139:chemically induced* / Q000175:diagnosis*; D011994:Recombinant Proteins; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D018608:Ultrasonography, Doppler
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins